Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Multi-cohort Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia

NCT04806035 is registered in ClinicalTrials.gov with TG Therapeutics, Inc. as lead sponsor.

NCT NCT04806035
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04806035 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Multi-cohort Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia
Lead sponsor
TG Therapeutics, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
April 28, 2021
Completion date
June 12, 2024
Enrollment
21 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

aggressive lymphoma, cll, dlbcl, follicular lymphoma, indolent lymphoma, marginal zone lymphoma, mcl, mediastinal large b-cell lymphoma, richter's transformation, sll